Annovis Bio, Inc. (ANVS)

USD 1.51

(2.7%)

Long Term Debt Summary of Annovis Bio, Inc.

  • Annovis Bio, Inc.'s latest annual long term debt in 2023 was - USD , down 0.0% from previous year.
  • Annovis Bio, Inc.'s latest quarterly long term debt in 2024 Q2 was - USD , down 0.0% from previous quarter.
  • Annovis Bio, Inc. reported annual long term debt of - USD in 2022, down 0.0% from previous year.
  • Annovis Bio, Inc. reported annual long term debt of - USD in 2021, down 0.0% from previous year.
  • Annovis Bio, Inc. reported quarterly long term debt of - USD for 2024 Q1, down 0.0% from previous quarter.
  • Annovis Bio, Inc. reported quarterly long term debt of - USD for 2023 Q4, down 0.0% from previous quarter.

Annual Long Term Debt Chart of Annovis Bio, Inc. (2023 - 2017)

Historical Annual Long Term Debt of Annovis Bio, Inc. (2023 - 2017)

Year Long Term Debt Long Term Debt Growth
2023 - USD 0.0%
2022 - USD 0.0%
2021 - USD 0.0%
2020 - USD -100.0%
2019 499.8 Thousand USD 0.0%
2018 - USD 0.0%
2017 - USD 0.0%

Peer Long Term Debt Comparison of Annovis Bio, Inc.

Name Long Term Debt Long Term Debt Difference
ADC Therapeutics SA 112.73 Million USD 100.0%
Alto Neuroscience, Inc. 151.33 Million USD 100.0%
Biohaven Pharmaceutical Holding Company Ltd. 27.56 Million USD 100.0%
Ginkgo Bioworks Holdings, Inc. 221.83 Million USD 100.0%
Nuvation Bio Inc. 2.03 Million USD 100.0%
Nuvation Bio Inc. 2.03 Million USD 100.0%
Arcus Biosciences, Inc. 110 Million USD 100.0%
Zymeworks Inc. 22.46 Million USD 100.0%